Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
ARDS
COVID-19
acute respiratory distress syndrome
inflammation
mesenchymal stem cell therapy
sepsis
Journal
Journal of intensive care medicine
ISSN: 1525-1489
Titre abrégé: J Intensive Care Med
Pays: United States
ID NLM: 8610344
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
6
3
2021
medline:
29
5
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times. Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 ± 0.2 versus 2.8 ± 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge. MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times.
RESULT
RESULTS
Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 ± 0.2 versus 2.8 ± 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge.
CONCLUSION
CONCLUSIONS
MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population.
Identifiants
pubmed: 33663244
doi: 10.1177/0885066621997365
pmc: PMC8145440
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-688Références
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Clin Invest. 2012 Aug;122(8):2731-40
pubmed: 22850883
Intensive Care Med. 2012 Oct;38(10):1573-82
pubmed: 22926653
Lancet Respir Med. 2019 Feb;7(2):154-162
pubmed: 30455077
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):25-32
pubmed: 17869550
N Engl J Med. 2013 Jun 6;368(23):2159-68
pubmed: 23688302
N Engl J Med. 2006 Jun 15;354(24):2564-75
pubmed: 16714767
Bone Marrow Transplant. 2018 Jul;53(7):852-862
pubmed: 29379171
Stem Cells Dev. 2020 Jul 1;29(13):811-822
pubmed: 32295491
Hum Mutat. 2017 Nov;38(11):1511-1520
pubmed: 28762252
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
Exp Hematol. 2006 Oct;34(10):1413-9
pubmed: 16982334
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Thorax. 2014 Sep;69(9):819-25
pubmed: 24891325
Cell Transplant. 2013;22(11):1981-2000
pubmed: 23107560
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Crit Care. 2020 Jul 11;24(1):420
pubmed: 32653043
Lancet Respir Med. 2014 Dec;2(12):1016-26
pubmed: 25465643
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758